ISSN 1941-5923


Interstitial granulomatous dermatitis successfully treated with etanercept

Zavier Shawkat Ahmed, Sabaa Joad, Manpreet Singh, Sabiha S. Bandagi

(Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, Queens Hospital Center, Jamaica, NY, USA)

Am J Case Rep 2014; 15:94-96

DOI: 10.12659/AJCR.890074

Published: 2014-03-01

Background: Interstitial granulomatous disease (IGD) is a rare skin condition that presents with erythematous and violaceous plaques, and may be associated with pruritus and pain. The cause remains unknown, but is often associated with autoimmune disease and drug-related adverse effects. It is diagnosed via biopsy, and the treatment remains unclear.
Case Report: We report a case of biopsy-proven IGD associated with rheumatoid arthritis that was treated successfully with etanercept therapy.
Conclusions: We emphasize that anti-TNF antibodies may be clinically effective for the treatment of IGD.

Keywords: etanercept, rheumatoid arthritis, Interstitial Granulomatous Dermatitis (IGD)